BURLINGTON, Mass. - Azenta, Inc. (NASDAQ:AZTA) announced Monday the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026, according to a press release statement. The leadership change comes as the stock has shown volatility, with shares posting a 6.9% gain over the past week despite trading down 32% year-to-date at $21.62.
Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer. The appointment follows the company's December 2025 Investor Day, where it outlined plans to scale global synthesis capabilities and drive growth across its Multiomics platform.
Ginger Zhou will step down from her role as President of the Multiomics business and will continue to support the company in an advisory capacity through November 2026.
Martin most recently served as Chief Executive Officer and a member of the Board of Directors of Maravai Life Sciences. Prior to that, he held senior leadership roles at Danaher Corporation, including Senior Vice President, Genomic Medicines, and President of Integrated DNA Technologies (IDT). Martin joined Danaher following their 2018 acquisition of IDT, after helping to lead the sale process.
Before the acquisition, Martin spent more than two decades at IDT in positions of increasing responsibility. He holds a bachelor's degree in biochemistry from the University of Iowa.
"Trey is exceptionally well positioned to lead the next phase of our Multiomics strategy," said Marotta. "He brings more than 30 years of leadership experience across life sciences operations, with deep expertise in scaling global synthesis and genomics platforms."
Azenta provides cold-chain sample management solutions and multiomics services for pharmaceutical, biotech, academic and healthcare institutions. The company is headquartered in Burlington, Massachusetts, with operations in North America, Europe and Asia.
In other recent news, Azenta Inc. reported first-quarter earnings that missed expectations, although its revenue of $149 million surpassed the consensus estimate of $147 million. The company faced a decline in gross margins, which decreased by 360 basis points compared to the previous year. Following these results, TD Cowen lowered its price target for Azenta to $30, maintaining a Hold rating on the stock. Additionally, Azenta announced the acquisition of UK Biocentre Limited for £20.5 million, including potential contingent consideration tied to specific milestones. The UK Biocentre generated approximately £15.3 million in revenue for the twelve months ending September 2025.
In terms of analyst ratings, Needham reiterated a Buy rating with a $44 price target, citing growth drivers after meetings with Azenta's executives. Meanwhile, KeyBanc maintained a Sector Weight rating following a recent industry conference, noting positive signals for the life science sector. Azenta also entered a strategic partnership with Frontier Space to advance space research, participating in the EGGS-2 mission to test experimental samples in microgravity environments.